Animal Health

Key Data – Animal Health

 

 

Q1 2015

 

Q1 2016

 

Change

 

 

€ million

 

€ million

 

Reported %

Fx & p adj. %

Fx & p adj. = currency- and portfolio-adjusted; Fx adj. = currency-adjusted

1

For definition see “Calculation of EBIT(DA) Before Special Items.”

2

For definition see “Statements of Cash Flows.”

Sales

 

386

 

408

 

+5.7

+8.8

Change in sales

 

 

 

 

 

 

 

Volume

 

+4.9%

 

+8.3%

 

 

 

Price

 

+1.5%

 

+0.5%

 

 

 

Currency

 

+10.9%

 

−3.1%

 

 

 

Portfolio

 

0.0%

 

0.0%

 

 

 

 

 

 

 

 

 

 

 

 

 

€ million

 

€ million

 

Reported %

Fx adj. %

Sales by region

 

 

 

 

 

 

 

Europe

 

119

 

128

 

+7.6

+9.2

North America

 

132

 

162

 

+22.7

+20.5

Asia / Pacific

 

75

 

67

 

−10.7

−8.0

Latin America / Africa / Middle East

 

60

 

51

 

−15.0

+3.3

 

 

 

 

 

 

 

 

EBITDA1

 

92

 

121

 

+31.5

 

Special items

 

(10)

 

(1)

 

 

 

EBITDA before special items1

 

102

 

122

 

+19.6

 

EBITDA margin before special items1

 

26.4%

 

29.9%

 

 

 

EBIT

 

65

 

114

 

+75.4

 

Special items

 

(32)

 

(1)

 

 

 

EBIT before special items1

 

97

 

115

 

+18.6

 

Gross cash flow2

 

72

 

86

 

+19.4

 

Net cash flow2

 

120

 

(20)

 

.

 

Sales

Sales of Animal Health in the first quarter of 2016 climbed by 8.8% (Fx & portfolio adj.) to €408 million. This growth was chiefly attributable to increased demand in the United States.

Best-Selling Animal Health Products

 

 

Q1 2015

 

Q1 2016

 

Change

 

 

€ million

 

€ million

 

Reported %

Fx adj. %

Fx adj. = currency-adjusted

Advantage™ product family

 

144

 

148

 

+2.8

+3.5

Seresto™

 

28

 

54

 

+92.9

+90.8

Drontal™ product family

 

31

 

32

 

+3.2

+7.2

Baytril™

 

30

 

28

 

−6.7

−3.2

Total

 

233

 

262

 

+12.4

+13.7

Proportion of Animal Health sales

 

60%

 

64%

 

 

 

Sales by product

  • We posted higher sales of our Advantage™ family of flea, tick and worm control products, mainly as a result of positive development in North America.
  • Sales of our Seresto™ flea and tick collar nearly doubled, thanks especially to higher demand in the United States and Europe.
  • Business with our Drontal™ line of wormers benefited from higher volumes in the United States.
  • Sales of our antibiotic Baytril™ fell slightly as expected because of generic competition.

Earnings

EBITDA before special items improved by 19.6% to €122 million in the first quarter of 2016 (Q1 2015: €102 million), due especially to the good development of business.

EBIT of Animal Health improved by a substantial 75.4% to €114 million, including special charges of €1 million (Q1 2015: €32 million).